KPL-404
Rheumatoid Arthritis
Phase 2In Development
Key Facts
About Kiniksa Pharmaceuticals
Founded in 2015 and publicly traded on NASDAQ, Kiniksa Pharmaceuticals is dedicated to advancing transformative therapies, with a core focus on cardiovascular diseases. Its key achievement is the 2021 FDA approval and commercial launch of ARCALYST for recurrent pericarditis, providing a critical treatment for a serious inflammatory heart condition. The company's strategy involves leveraging validated immune-modulating pathways, pursuing multiple indications for its assets, and forming strategic collaborations to expand its global reach and pipeline potential.
View full company profileTherapeutic Areas
Other Rheumatoid Arthritis Drugs
| Drug | Company | Phase |
|---|---|---|
| Early Detection Test for Rheumatoid Arthritis | Age Labs | Development |
| CORTONE (cortisone) | Merck | Commercial |
| Kevzara (sarilumab) | Regeneron Pharmaceuticals | Approved |
| Actemra (tocilizumab) | Chugai Pharmaceutical | Approved |
| Tocilizumab | Biocon | Filed |
| Humira | Abbott India | Approved |
| Tibulizumab (ZB-106) | Zura Bio | Phase 1b |
| Zunsemetinib (ATI-450) | Aclaris Therapeutics | Phase 2b |
| Natrunix Program | XBiotech | Not Specified |
| LEAPS Technology | CEL-SCI | Pre-clinical |
| Piclidenoson (CF101) | Can Fite Biopharma | Phase 3 |
| Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure) | LFB | Pre-clinical |